CD24 and COVID-19: Thus, Siglec-9is a therapeutic target to inhibit potentially fatal hyperinflammationassociated with COVID-19 in an analogous fashion to the highly effectivetherapeutics currently aimed at the Siglec-10/CD24 interaction.